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For the past 41 years, metal-based drugs have been widely used for the treatment of cancer.
Cisplatin and follow-up drugs carboplatin (Paraplatin™) and oxaliplatin (Eloxatin™) have been
the gold standard for metallodrugs as antineoplastic agents in clinical settings. Although effective,
these drugs, either alone or in combination therapy, have faced a number of clinical challenges resulting
from their limited spectrum of activity, high toxicity producing significant side effects, resistance,
poor water solubility, low bioavailability, and short circulating time. In the past two decades, various
unconventional non-platinum metal-based agents have emerged as potential alternatives for cancer
treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and
other chemotherapeutic agents. Research in this area has recently intensified with a relevant number of
patents and clinical trials, in addition to reports in scientific journals including some excellent reviews
and books published in 2018–2019 [1–6]. Some recent highlights include ongoing clinical trials with
gold auranofin for the treatment of small and non-small lung cancer and high-grade ovarian, fallopian
tube, and peritoneal cancer [7,8], as well as upcoming clinical trials with copper derivatives in metastatic
pancreas cancer [9], and phase II clinical trials with a ruthenium-based photodynamic compound
(TLD-1433) for non-muscle invasive bladder cancer [10]. In parallel to the synthesis of coordination
and organometallic compounds comprising different metals and unconventional platinum-based
derivatives, researchers have also worked on optimizing the mechanistic and pharmacological features
of promising drug candidates [1,2]. This Special Issue is devoted to some of the latest advances in
anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation,
targeting, and delivery strategies aimed at improving their pharmacological profile. Twelve medicinal
inorganic chemistry groups from different countries have provided contributions to this Special Issue.
Three groups contributed with superb and well-organized reviews. In the area of unconventional
anticancer agents, Romero-Canelón et al. completed an overview on key ruthenium drug candidates
and the knowledge acquired during the past two decades with the aim of discussing ideas to optimize
their chemical design by incorporating new concepts [11]. Tinoco et al. contributed a review on the
significant roles that copper and iron play in the molecular pathways involved in cell proliferation and
metastasis, and the evaluation of selected chelators for these metals showing promise as anticancer
drugs [12]. Efforts to optimize the pharmacological profile (cellular delivery, efficacy, and tumor
responsiveness) of these chelators as well as a description of analytical tools used to quantify the metal
levels and to track the metals intracellularly are described [12]. Lastly, Mieszawska et al. contributed a
timely comprehensive review on the use of nano-based systems and biomacromolecules as carriers to
facilitate the in vivo application of metal-based drugs (solubility, bioavailability, and delivery to tumor
tissues). This review focuses on complexes comprising platinum, ruthenium, copper, and iron [13].

Inorganics 2019, 7, 88; doi:10.3390/inorganics7070088

www.mdpi.com/journal/inorganics

Inorganics 2019, 7, 88

2 of 4

This Special Issue also contains nine original research articles. Seven of these articles focus on
unconventional metal-based agents with promising anticancer activity and/or their interactions with
relevant cancer biomolecular targets. Komeda et al. report on dinuclear platinum(II) complexes
containing ammonia and a bridge ligand between the platinum(II) centers consisting of a tetrazolate
moiety with lipophilic substituents in the C5 position [14]. The authors describe the interactions of
these complexes with β-cyclodextrin and its positive influence on the in vitro and in vivo activity
of the dinuclear platinum(II) complexes in colorectal cancer cells and tumors [14]. Gómez-et al.
describe the synthesis and cytotoxicity of new trans-platinum complexes containing iodido and amine
ligands, and their chemical behavior in solution and reactivity towards biomolecules [15]. They found
a beneficial effect (increased reactivity towards model nucleobase 5’-GMP) when exposed to UVA
irradiation. Density functional theory (DFT) calculations for these compound, and comparisons of
reactivity and biological activity with other iodide platinum(II) derivatives are also included in this
article [15].
This Special Issue also collects reports on the synthesis and anticancer properties of compounds
containing metals other than platinum [16–20]. Navarro et al. report cell viability assays on selected
human cancer cell lines of cationic ruthenium(II) compounds based on p-cymene, triphenylphosphine,
and biologically active clotrimazole and ketoconazole as ligands [16]. Preliminary studies on the
cell cycle and mechanism of cell death as well as the promising anti-migration activity of a selected
compound with clotrimazole on a triple negative breast tumor cancer cell line were reported [16].
Da Costa Ferreira et al. contributed to this issue with a report on new copper(II) and zinc(II) complexes
containing new oxindolimine ligands [17]. The cytotoxicity of these compounds against hepatocellular
carcinoma and neuroblastoma cancer cell lines, as well as their reactivity toward Calf Thymus DNA
and human serum albumin, was investigated. The main conclusion is a confirmation of DNA as an
important target for these compounds and an indication that oxidative damage is not the leading
mechanism of cell death [17]. Three other leading medicinal inorganic chemistry groups contributed
original articles on gold compounds [18–20]. Gimeno et al. describe the excellent cytotoxicity observed
in several cancer cell lines by neutral gold(I) compounds containing biologically relevant thiolates
and a new phosphine ligand bearing a thiophene molecule [18]. Farrell and Beaton report novel
cationic gold(III) compounds containing the 1-methylcytosine ligand and chelating diamines for
greater specificity toward biomolecules, with the ultimate goal of avoiding undesirable nonselective
interactions and providing a better understanding of the speciation [19]. They describe the interactions
of these compounds with models for the HIV nucleocapsid protein NCp7. More specifically, the
authors report the affinity of the gold(III) complexes with the “essential” tryptophan of the C-terminal
zinc finger motif of NCp7 by fluorescence and 1 H NMR spectroscopy, and included results on the
specifics of this interaction by circular dichroism spectroscopy and electrospray-ionization mass
spectrometry. A nearly immediate interaction with the apopeptide and indications of reactions via a
charge transfer mechanism is described for the first time [19]. Casini et al. present findings on the
synthesis and characterization of a series of cationic and neutral gold(III) compounds featuring a
pyridine-benzimidazole scaffold [20]. The potent and selective inhibition of the membrane water and
glycerol channels aquaporins (aquaglyceroporin, AQP3) in human red blood cells (hRBC) and a higher
activity of the neutral compounds on melanoma A375 cells with marked membrane level expression
of AQP3 are described. The potential of these compounds in the development of chemical probes to
study the function of this protein isoform in biological systems is also highlighted [20].
This Special Issue contains a relevant research article by Meier-Menches et al. on the development
and validation of liquid-chromatography-based methods to assess the lipophilicity of cytotoxic
platinum(IV) complexes [21], which is of interest to the medicinal inorganic chemistry community due
to: (1) the current availability of high-performance liquid chromatography (HPLC) instruments in
research laboratories, and (2) the potential of obtaining chromatographic lipophilicity parameters (ϕ0
that can be interconverted to Log P and Log Kw) for other metal-based compounds [21].
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Lastly, Salassa et al. provide a contribution on functionalized upconverting nanoparticles (UCNPs)
with bone-targeting phosphonate ligands for imaging purposes [22]. The authors report the synthesis
and characterization of a new series of phosphonate-functionalized NaGdF4:YbmEr UCNPs that show
affinity for hydroxyapatite, which is the inorganic constituent of bones, and discuss their potential as
bone targeting multimodal (MRI/PET) imaging agents. In vivo biodistribution studies of 18 F-labbeled
functionalized UCPNs in rats revealed the favored accumulation of nanoparticles in bones over
time [22].
I truly hope that the readers find the open access format articles in this Special Issue timely
and relevant, and that the Issue contributes to increasing awareness about the real potential of
optimized metal-based drugs as competitive anticancer agents. The inorganic medicinal community
has demonstrated that the assumption that all anticancer metallodrugs behave as cisplatin and related
platinum-based compounds in terms of spectrum of activity and selectivity is no longer valid.
Finally, I want to thank all the authors for their excellent and diverse contributions to this Special
Issue as well as the participating reviewers for their high quality suggestions and evaluations of
the articles submitted. Lastly, this Special Issue would not have been possible without the constant
dedication, support, and patience of the members of the editorial staff of Inorganics from the beginning
to the end of the process. I am very grateful to them.
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